Published in Circulation on April 21, 1998
Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation (2008) 1.64
Statin trials and goals of cholesterol-lowering therapy. Circulation (1998) 1.60
Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect. CMAJ (2005) 1.43
Statins in the primary prevention of cardiovascular disease. Nat Rev Cardiol (2013) 1.12
Low density lipoprotein cholesterol, statins and cardiovascular events: a meta-analysis. Clin Res Cardiol (2006) 1.01
Efficacy of simvastatin treatment of valvular interstitial cells varies with the extracellular environment. Arterioscler Thromb Vasc Biol (2008) 1.01
3-Hydroxy-3-methylglutaryl CoA reductase inhibitors up-regulate transforming growth factor-beta signaling in cultured heart cells via inhibition of geranylgeranylation of RhoA GTPase. Proc Natl Acad Sci U S A (1999) 0.99
HMG-CoA reductase inhibitors enhance phagocytosis by upregulating ATP-binding cassette transporter A7. Atherosclerosis (2011) 0.84
Statins and total (not LDL) cholesterol concentration and outcome of myocardial infarction: results from a meta-analysis and an observational study. Eur J Clin Pharmacol (2009) 0.83
The Nuclear Orphan Receptor NR4A1 is Involved in the Apoptotic Pathway Induced by LPS and Simvastatin in RAW 264.7 Macrophages. Immune Netw (2014) 0.82
Prescription medication burden in patients with newly diagnosed diabetes: a SUrveillance, PREvention, and ManagEment of Diabetes Mellitus (SUPREME-DM) study. J Am Pharm Assoc (2003) (2014) 0.81
Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study. PLoS One (2015) 0.80
Physiogenomic analysis of statin-treated patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein cholesterol? Pharmacogenomics (2010) 0.79
Effect of rosuvastatin on concentrations of plasma lipids, urine and plasma oxidative stress markers, and plasma high-sensitivity C-reactive protein in hypercholesterolemic patients with and without type 2 diabetes mellitus: A 12-week, open-label, pilot study. Curr Ther Res Clin Exp (2009) 0.77
[The role of lipid metabolism in the prevention of coronary heart disease]. Z Kardiol (2005) 0.77
Debate: "How low should LDL cholesterol be lowered?" Viewpoint: "It doesn't need to be very low" Curr Control Trials Cardiovasc Med (2001) 0.76
Colesevelam hydrochloride: evidence for its use in the treatment of hypercholesterolemia and type 2 diabetes mellitus with insights into mechanism of action. Core Evid (2012) 0.76
Lipid Lowering Therapy to Modify Plaque Microstructures. J Atheroscler Thromb (2017) 0.75
All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT. Data Brief (2016) 0.75
Laboratory Medicine in the Clinical Decision Support for Treatment of Hypercholesterolemia: Pharmacogenetics of Statins. Clin Lab Med (2016) 0.75
Debate: "How low should LDL cholesterol be lowered for optimum prevention of vascular disease?" Viewpoint: "Below 100 mg/dl" Curr Control Trials Cardiovasc Med (2001) 0.75
Statins for primary prevention: strategic options to save lives and money. J R Soc Med (2004) 0.75
Influences of age, sex, and LDL-C change on cardiovascular risk reduction with pravastatin treatment in elderly Japanese patients: A post hoc analysis of data from the Pravastatin Anti-atherosclerosis Trial in the Elderly (PATE). Curr Ther Res Clin Exp (2006) 0.75
The effects of rosuvastatin on lipid-lowering, inflammatory, antioxidant and fibrinolytics blood biomarkers are influenced by Val16Ala superoxide dismutase manganese-dependent gene polymorphism. Pharmacogenomics J (2016) 0.75
Hypertriglyceridemia-why, when and how should it be treated? Z Kardiol (2005) 0.75
Variations in Echogenicity in Carotid and Femoral Atherosclerotic Plaques with Pycnogenol + Centella Asiatica Supplementation. Int J Angiol (2016) 0.75
Hemorrhagic colitis associated with a rare Escherichia coli serotype. N Engl J Med (1983) 25.72
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med (1996) 23.76
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med (1992) 18.74
Biochemical identification of new species and biogroups of Enterobacteriaceae isolated from clinical specimens. J Clin Microbiol (1985) 17.42
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA (2000) 12.86
Laboratory investigation of hemorrhagic colitis outbreaks associated with a rare Escherichia coli serotype. J Clin Microbiol (1983) 10.23
Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation (1990) 9.74
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med (2001) 9.31
Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med (2011) 7.62
Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med (2001) 7.05
Factors influencing infarct size following experimental coronary artery occlusions. Circulation (1971) 7.04
Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med (1996) 6.92
The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation (1982) 5.56
The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med (2001) 5.50
TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation (2000) 5.15
A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med (1995) 4.94
Escherichia fergusonii and Enterobacter taylorae, two new species of Enterobacteriaceae isolated from clinical specimens. J Clin Microbiol (1985) 4.52
TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation (1996) 4.41
Myocardial infarct size and ventricular function in rats. Circ Res (1979) 4.33
Effects of beta-adrenergic blockade on the cardiac response to maximal and submaximal exercise in man. J Clin Invest (1965) 4.23
Myocardial reperfusion: a double-edged sword? J Clin Invest (1985) 4.12
A trial of two strategies to modify the test-ordering behavior of medical residents. N Engl J Med (1980) 3.98
Control of heart rate by the autonomic nervous system. Studies in man on the interrelation between baroreceptor mechanisms and exercise. Circ Res (1966) 3.95
H7 antiserum-sorbitol fermentation medium: a single tube screening medium for detecting Escherichia coli O157:H7 associated with hemorrhagic colitis. J Clin Microbiol (1985) 3.91
Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation (1999) 3.90
Sporadic cases of hemorrhagic colitis associated with Escherichia coli O157:H7. Ann Intern Med (1984) 3.88
Atypical biogroups of Escherichia coli found in clinical specimens and description of Escherichia hermannii sp. nov. J Clin Microbiol (1982) 3.84
Idiopathic hypertrophic subaortic stenosis. Clinical analysis of 126 patients with emphasis on the natural history. Circulation (1968) 3.82
A comparison of management patterns after acute myocardial infarction in Canada and the United States. The SAVE investigators. N Engl J Med (1993) 3.75
Control of myocardial oxygen consumption: physiologic and clinical considerations. Am J Cardiol (1971) 3.68
Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation (2000) 3.66
Aortic stenosis. Circulation (1968) 3.49
Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet (2000) 3.39
Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation (1999) 3.26
Non-O group 1 Vibrio cholerae gastroenteritis in the United States: clinical, epidemiologic, and laboratory characteristics of sporadic cases. Ann Intern Med (1981) 3.25
Defective cardiac parasympathetic control in patients with heart disease. N Engl J Med (1971) 3.24
Characterization of biochemically atypical Vibrio cholerae strains and designation of a new pathogenic species, Vibrio mimicus. J Clin Microbiol (1981) 3.19
Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation (1998) 3.19
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet (2009) 3.13
Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med (1997) 3.13
Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis (1998) 3.09
Acute coronary syndrome without ST elevation: implementation of new guidelines. Lancet (2001) 3.07
Mechanism of action of calcium-channel-blocking agents. N Engl J Med (1982) 2.99
Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med (1988) 2.98
High-molecular-weight plasmid correlates with Escherichia coli enteroinvasiveness. Infect Immun (1982) 2.95
Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation (2000) 2.93
A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Lancet (2001) 2.78
Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation (1994) 2.74
Increased pulse pressure and risk of heart failure in the elderly. JAMA (1999) 2.74
Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators. N Engl J Med (1992) 2.72
Clinical significance of mitral regurgitation after acute myocardial infarction. Survival and Ventricular Enlargement Investigators. Circulation (1997) 2.64
Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation (1999) 2.59
Influence of the thyroid state on the intrinsic contractile properties and energy stores of the myocardium. J Clin Invest (1967) 2.51
Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass. N Engl J Med (1996) 2.49
Effect of antihypertensives on sexual function and quality of life: the TAIM Study. Ann Intern Med (1991) 2.49
VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation (2000) 2.47
Extrachromosomal nature of hydrogen sulfide production in Escherichia coli. J Bacteriol (1971) 2.45
Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol (1991) 2.40
Differential effect of steady versus oscillating flow on bone cells. J Biomech (1998) 2.38
Unstable angina: an etiologic approach to management. Circulation (1998) 2.31
The effects of nitroglycerin and amyl nitrite on arteriolar and venous tone in the human forearm. Circulation (1965) 2.30
Oxygen consumption of the heart. Newer concepts of its multifactoral determination. Am J Cardiol (1968) 2.29
Correlation between adherence to HeLa cells and serogroups, serotypes, and bioserotypes of Escherichia coli. Infect Immun (1985) 2.28
Coronary-artery surgery at the crossroads. N Engl J Med (1977) 2.28
Reduction of experimental myocardial infarct size by corticosteroid administration. J Clin Invest (1973) 2.28